The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Funny, did you get chart I emailed you? showed this before it broke last descending wedge, I had a good run on it but sold out to early. Got my offer on pub excepted today, so if you are in Devon real ale all round!
This is obviously purely from a TA perspective as i know nothing of its fundementals.
Tempus likes Advanced Medical Solutions, which makes wound dressings and treatments. A recent acquisition in Germany also allows it to sell sutures and collagens (with acceptance for the range by the NHS - a big market). Its LiquiBand wound sealant works on the same basis as superglue and offers significant sales prospects. Trading on about 14.5 times future earnings AMS is a buy for growth prospects and takeover possibilities.
Wounds treatment firm Advanced Medical Solutions was in demand after it posted a jump in profits and raised its dividend. Profit before tax was up 72% to £4.5m on revenues that were up 52% to £24.8m in the first half of the year. The firm pushed up its interim dividend to 0.17p per share, an increase of 17.2% on the year before. Chairman, Dr Don Evans, said the first half of 2012 hd seen significant progress by AMS, with its product LiquiBand continuing to increase its market share in the US. "Despite the ongoing effects of the Euro on revenues, as highlighted previously, we expect to meet current market expectations for profit for the full-year," he said." Evans also noted a strong performance by its wound dressing ActivHeal in the UK and an excellent initial contribution from the firm's recent acquisition of German firm Resorba. "The second half is also expected to benefit from stronger silver alginate sales, initial trilaminate foam revenues and an additional boost in the US from LiquiBand Flex," he said. "Further out, we have a number of exciting developments coming through our R&D pipeline which, combined with further strong progress anticipated in our existing businesses, lead the board to be very optimistic about our long term prospects," the Chairman added.
Well Ladies and Gentlemen if these are the results we get when the board felt we'd fall behind their expectations I'd like to see the results when we finally meet their targets. As always thanks to Don and the team for all your hard work and congratulations on the more than steady progress of the company.
Commenting on the results Dr. Don Evans, Chairman of AMS, said: "The first half of 2012 has again seen significant progress by AMS, with LiquiBand® continuing to increase its market shares in the US, another strong performance by ActivHeal® in the UK and an excellent initial contribution from RESORBA®. In addition to further gains from these parts of our business, the second half is also expected to benefit from stronger silver alginate sales, initial trilaminate foam revenues and an additional boost in the US from LiquiBand® Flex. Further out, we have a number of exciting developments coming through our R&D pipeline which, combined with further strong progress anticipated in our existing businesses, lead the Board to be very optimistic about our long term prospects."
Business Highlights: • In the US, LiquiBand® market share by volume increased to 6% in the hospital segment and 10% in the alternate site segment • ActivHeal® continues its excellent progress in the NHS, with a 40% increase in revenues • New trilaminate foam range has achieved CE certification and has now been launched • Silver alginate destocking finished and partners are growing sales faster than the wider market • RESORBA® integration is going well and progressing to plan - LiquiBand® sales in Germany via RESORBA® have increased by 15% • Own brands now account for over 50% of revenues (2011 H1: approximately 25%) Subsequent Events: • First contract award for LiquiBand® Flex with a major US hospital group, and agreements now in place with five additional US distributors • Successful contract award to supply NHS with sutures, haemostats as well as tissue adhesives from October 2012
Interim Results for the six months ended 30 June 2012 Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces its interim results for the six months ended 30 June 2012. Financial Highlights: • Group revenue up 52% to £24.8 million (2011 H1: £16.3 million), representing growth of 55% on a constant currency basis¹ • Underlying like-for-like Group revenue on a constant currency basis (excluding RESORBA®) flat at £16.0 million • Adjusted2 operating margin up 660 bps to 23.2% (2011 H1:16.6%) • Adjusted2 profit before tax up 98% to £5.4 million (2011 H1: £2.7 million) • Profit before tax up 72% to £4.5 million (2011 H1: £2.6 million) • Adjusted2 diluted earnings per share up 30% to 2.27p (2011 H1: 1.74p) • Fully diluted earnings per share up 11% to 1.87p (2011 H1: 1.68p) • Operating cash flow before exceptional items3 of £5.6 million (2011 H1: £1.5 million) • €2 million of €25 million loan to acquire RESORBA® has been repaid ahead of schedule • Interim dividend of 0.17p per share (2011 H1: 0.145p), a 17.2% increase
http://www.investegate.co.uk/Article.aspx?id=201209050700095022L
Singer Capital upgraded its stance on Advanced Medical Solutions (AMS) from "fair value" to "buy" with an increased target price of 82p, from 80p. The broker said that the shares have been impacted by a number of short-term factors such as the weakness of the Euro and delays in orders for its LiquiBand product. However, Singer believes that the successful integration of Resorba would offer significant growth potential for the wound care technology developer, but noted that effects will not be seen until next year. On the broker's forecasts the shares trade on a prospective earnings multiple of 13.3 times for 2012, falling to 11.5 times in 2013
A "roll-stock" order for the group's foam product received in 2011 will not be repeated in 2012, further reducing turnover. In a statement to the company's AGM on Tuesday, however, AMS's Chairman Dr Don Evans stressed the revenue decline will only have a "negligible" effect on profits.
Advanced Medical Solutions, the wound care specialist, has warned currency movements and the end of a rolling order are likely to hit full year revenues. AMS bought a German firm, RESORBA, in 2011, the effect being that more revenues are denominated in euros. The euro's current weakness means the company will see revenues decline when income is translated into sterling
A regular down to 65 and up to 95/99 cycle - hit bottom before the market crashed and now moving rapidly up despite the Euro turmoil - got in low before the up curve plateaus in a few weeks
Cheers fella I appreciate your thoughts on the topic !
I believe it means nothing. Very small volume, House broker moved up during the day and the market was very quiet. There is no news expected until end march early april as results arrive.Long boring period before us.
Mmmmh around £14,000 sells and £100,000 buys today and the share price drops 2.37 %....now what could that mean I wonder ??
They made a profit of 2 million euroes in 2010 and this was after exceptional cost of 2.1 million and Financial cost of 2.3 million...looks like the assets total around 40 million euroes. If you go to this website and click on ''Acquisation of Resoba' under the news section it gives alot more detail plus what AMS thinks are the benefits in acquiring Resorba would be together with their plans if everything goes through. http://www.iii.co.uk/investment/detail?code=cotn:AMS.L
Haven't had time to re-assess the fundamentals vs the current share price yet, annoyed with myself as I've missed another rise here, nevermind! Have you looked at the numbers of Resorba, do you know if they were making money and how much this might add to AMS's operating profit?
...reasonably well dispite nearly 4 million pounds worth of share being unloaded by someone this morning. It's a little down on iii but hardly any effect at all. Be interesting to see how she finshes.
Who knows with shares Pete especially where there's a placing involved. If there's not too many queueing for those shares then the price may well drift back down a little towards the 72 mark. But in my opinion there's still a lot of potential in the different markets around the World and AMS are slowly starting to cover the different options with the movement in the USA last year and this and now the acquisition of Resorba. Good luck which ever way you jump Pete.
... have to admit I was one of the ones holding out for 70p, been watching this for a while and if I hadn't been traveling I would have probably been in at 73p, gutted, but potential still looks good though, but 73p was a bargain looking at fundamentals
Yeah a great acquisition indeed Mulled and AMS yet again looking to expand globally and get a solid foothold in the European Market, next stop Asia no doubt. Looks like Charles Stanley got a wiff of the placing, but a bad call for all those holding out for 70p. With the results due before Christmas this could push on into the nineties again and another run at the one pound barrier. I guess it depends whether there's a queue of institutions and fund managers for the placed shares at 72p.
ommenting on the Acquisition, Chris Meredith, Chief Executive Officer of AMS said: "Part of our core growth strategy has been to examine potential acquisition opportunities that strengthen our business with complementary technologies and greater market access, specifically in relation to the operating room segment of our global business. It is rare to find a business that fits our criteria as well as RESORBA does. We have known RESORBA for a number of years as a result of our LiquiBand® relationship, and I am confident that the enlarged AMS Group will benefit from a wide range of commercial opportunities that will enable us to continue the strong progress made in recent years."
Placing of 47,236,112 new Ordinary Shares in AMS at a price of 72 pence per share to raise approximately £34.0 million in connection with the proposed acquisition of RESORBA Wundversorgung GmbH & co. KG The Board of AMS (AIM: AMS), the global medical technology company, is pleased to announce today the proposed acquisition of RESORBA, a long established wound care and wound closure business headquartered in Germany for a total cash consideration of €63.8 million (approximately £55 million) on a debt-free, cash-free basis to be paid, in full, on completion. To fund the acquisition, the Board of AMS also announces today a non pre-emptive institutional placing (the "Placing") of 47,236,112 new Ordinary Shares in AMS (the "Placing Shares") at a price of 72 pence per Placing Share (the "Placing Price"), to raise approximately £34.0 million (£30.5 million net of acquisition and placing expenses), together with a €25.0 million term loan facility. • The acquisition of RESORBA fulfils all of AMS's strategic acquisition criteria and provides a number of commercial synergy opportunities as it: • Broadens the Group's technology portfolio in both wound care and wound closure; • Provides direct sales capability into the operating room in Germany, Czech Republic and Russia; • Provides significant cross-selling opportunities and product development potential; • Provides access to a new market - oral surgery; • Leverages AMS's global distribution network and regulatory expertise to bring existing RESORBA products to new markets; and • Provides development opportunities in the short, medium and long term • RESORBA is well known to AMS as it currently distributes its LiquiBand® wound closure product and has done for more than eight years • Acquisition is expected to be earnings per share enhancing in the twelve months ending 31 December 20121 • Senior management of RESORBA will be joining the Enlarged Group and investing a material proportion of their net proceeds from the Acquisition in AMS shares • Significant shareholder support for the Placing